Notable Labs

Notable Labs Net Margin

The Net Profit Margin of Notable Labs (NTBLQ) as of Nov 10, 2026 is -3,633.55 %. In the previous year, Net Profit Margin was -4,893.94 % — a change of -25.75% (higher).

Net Margin

-3,633.55 %

YoY

-25.75%

Last updated:

Net Profit Margin of Notable Labs is 2023 -3,633.55 % . Net Profit Margin of Notable Labs was 2022 -4,893.94 % . It decreases by -25.75% higher compared to the previous year.

For Notable Labs, the net margin of -3,633.5% is down versus -3,464.3% a few years ago.

The Notable Labs Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2017
-73.16 USD
Jan 1, 2018
-3,474.58 USD
Jan 1, 2019
-3,464.29 USD
Jan 1, 2020
-2,633.70 USD
Jan 1, 2021
-3,885.71 USD
Jan 1, 2022
-4,893.94 USD
Jan 1, 2023
-3,633.55 USD
The Notable Labs Net Margin history
YEARNet MarginYoY
-3,633.55 %-25.75%
-4,893.94 %+25.95%
-3,885.71 %+47.54%
-2,633.70 %-23.98%
-3,464.29 %-0.30%
-3,474.58 %+4,649.27%
-73.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Net Profit Margin of Notable Labs is -3,633.55 % in 2023.

Net Profit Margin of Notable Labs changed from -4,893.94 % to -3,633.55 %, representing a -25.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Notable Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Notable Labs

All Key Metrics — Notable Labs